Get the Stockscreener App
349.92
0.44%
-1.56
After Hours:
345.59
-4.33
-1.24%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $349.92, with a volume of 2.13M.
It is down -0.44% in the last 24 hours and down -6.81% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$351.48
Open:
$353.3
24h Volume:
2.13M
Relative Volume:
0.78
Market Cap:
$188.63B
Revenue:
$36.74B
Net Income/Loss:
$7.71B
P/E Ratio:
24.58
EPS:
14.2333
Net Cash Flow:
$8.10B
1W Performance:
-4.86%
1M Performance:
-6.81%
6M Performance:
+22.60%
1Y Performance:
+10.82%
1-Day Range:
$347.85
$356.32
1-Week Range:
$347.85
$372.98
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
349.92 | 189.47B | 36.74B | 7.71B | 8.10B | 14.23 |
|
LLY
Lilly Eli Co
|
917.50 | 819.81B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
237.60 | 571.52B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
206.23 | 368.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
188.93 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
148.19 | 285.86B | 54.72B | 14.02B | 15.32B | 7.1855 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Rocatinlimab Halt Puts Spotlight On Amgen Pipeline Risks And Valuation - simplywall.st
Amgen Expands Oncology Pipeline With New Phase 1 AMG 436 Study in MSI-H/dMMR Tumors - TipRanks
AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock? - TradingView
Amgen (NASDAQ:AMGN) Given New $390.00 Price Target at Wells Fargo & Company - MarketBeat
Wells Fargo Adjusts Price Target on Amgen to $390 From $375, Maintains Equalweight Rating - marketscreener.com
GAMMA Investing LLC Raises Stock Position in Amgen Inc. $AMGN - MarketBeat
Stillwater Wealth Management Group Purchases New Shares in Amgen Inc. $AMGN - MarketBeat
Investment Research Partners LLC Invests $1.06 Million in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. stock faces pressure amid 2026 guidance scrutiny and sector headwinds - AD HOC NEWS
93,962 Shares in Amgen Inc. $AMGN Acquired by CIBC Bancorp USA Inc. - MarketBeat
Amgen Inc. $AMGN Shares Purchased by AIA Group Ltd - MarketBeat
Amgen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Amgen Inc. (AMGN) collaborates on ending anti-OX40 clinical studies - MSN
AMGEN INC. (AMGN) - MSN
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Wilmington Savings Fund Society FSB Reduces Holdings in Amgen Inc. $AMGN - MarketBeat
Tcfg Wealth Management LLC Has $1.77 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Valuation Check As Recent Share Momentum Cools - simplywall.st
Amgen Inc. $AMGN is Mizuho Markets Cayman LP's 4th Largest Position - MarketBeat
Danske Bank A S Buys Shares of 358,171 Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Avity Investment Management Inc. - MarketBeat
Captrust Financial Advisors Has $137.07 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report - AOL.com
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance Singapore
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position - Insider Monkey
Amgen Helps Bring Youth Soccer Clinic to Greater Los Angeles with Skills, Drills and Fun Amid Run-up to 2026 World Cup - Amgen
Amgen Inc. $AMGN Shares Purchased by Mariner LLC - MarketBeat
6,457 Shares in Amgen Inc. $AMGN Acquired by Marshall Investment Management LLC - MarketBeat
Amgen Inc. $AMGN Stock Position Lessened by Mizuho Markets Cayman LP - MarketBeat
National Bank of Canada FI Purchases 863,216 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. Shs Thailand Depositary Receipts Repr 1 Sh Trade Ideas — SET:AMGN06 - TradingView
Exclusive: Amgen's $900M New Albany plant expansion 'setting the standard' - The Business Journals
Focus Partners Wealth Acquires 8,839 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Position Trimmed by CSM Advisors LLC - MarketBeat
Alliancebernstein L.P. Sells 444,604 Shares of Amgen Inc. $AMGN - MarketBeat
Marine Drug Market: Ready To Fly on high Growth Trends | Pfizer, AstraZeneca, Amgen - openPR.com
Amgen And Sanofi End Repatha IP Fight Heard By Justices - Law360
Here’s Why Amgen’s Free Cash Flow Could Nearly Double in 2026 - TIKR.com
Is Amgen Inc. (AMGN) a Good Buy at the Moment? - Bitget
Is Trending Stock Amgen Inc. (AMGN) a Buy Now? - Yahoo Finance
Biotechnology Market Is Booming So Rapidly | Abbott Laboratories, Amgen Inc., GlaxoSmithKline - openPR.com
Hilltop Holdings Inc. Boosts Stock Position in Amgen Inc. $AMGN - MarketBeat
Elevation Point Wealth Partners LLC Buys 5,370 Shares of Amgen Inc. $AMGN - MarketBeat
Bank of Nova Scotia Purchases 60,794 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Position Decreased by Ameriprise Financial Inc. - MarketBeat
Amgen Inc. Stock Holds Defensive Ground Near 366 USD as Biotech Giant Targets 12% Annual Gain - AD HOC NEWS
Amgen TrumpRx Discounts Put Drug Pricing And Growth Story In Focus - simplywall.st
Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies - Insider Monkey
Amgen’s TrumpRx Discounts and Dividend Hike Might Change The Case For Investing In Amgen (AMGN) - Yahoo Finance
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.13%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):